www.genotec-frankfurt.de/top-5-simple-virtual-deal-software-for-beginners/
The focus of the industry on living organisms of the human species and the strict regulations that it imposes are unique to business leaders. These features make the industry an ideal platform for innovation. They have led to major breakthroughs in biofuels, crop yields, and life-saving pharmaceuticals.
When it comes to strategies that generate revenue biotech start-ups have a myriad of options. The majority choose either a technology partnership or an asset creation-and-out licensing strategy. Technology-based partnerships can produce higher revenue and lower financial risk, whereas assets creation and outlicensing strategies can generate significantly more returns. A increasing number of biotechs in the research stage use a hybrid strategy that combines the two approaches.
Those who opt for an approach that is focused on product development can achieve commercial success when they are able to get their pipeline to a suitable stage and also attract a significant Pharma partner or an investor with deep pockets. This can be an expensive proposition. It is crucial to consider the balance between opportunistic strategies in using outside resources and making proper scientific decision-making regarding homegrown projects.
The “platform” model is a second option to generate revenue. It is less costly than development based on product, but involves significant risk. In this model, a biotech owns and develops its platform technology before collaboration with big pharma firms to generate a portfolio of drug discovery projects that specifically target diseases (i.e. disease that is x within biology and y). This is the method Advinus Therapeutics and a few others have followed.